rabbit anti-thymocyte globulin - single dose + mycophenolate mofetil + rabbit anti-thymocyte globulin - 4 doses + sirolimus + tacrolimus
ApprovedCompleted 0 watching 0 views this week🔥 Hot
84
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
End-stage Renal Disease
Conditions
End-stage Renal Disease
Trial Timeline
Apr 1, 2004 → Jun 1, 2011
NCT ID
NCT00556933About rabbit anti-thymocyte globulin - single dose + mycophenolate mofetil + rabbit anti-thymocyte globulin - 4 doses + sirolimus + tacrolimus
rabbit anti-thymocyte globulin - single dose + mycophenolate mofetil + rabbit anti-thymocyte globulin - 4 doses + sirolimus + tacrolimus is a approved stage product being developed by Sanofi for End-stage Renal Disease. The current trial status is completed. This product is registered under clinical trial identifier NCT00556933. Target conditions include End-stage Renal Disease.
Hype Score Breakdown
Clinical
30
Activity
20
Company
9
Novelty
10
Community
12
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00556933 | Approved | Completed |
Competing Products
20 competing products in End-stage Renal Disease